Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.
/ 15 items
#AZN↓
AstraZeneca Shares Jump as COPD Drug Tozorakimab Delivers Positive Results
AstraZeneca’s experimental drug tozorakimab significantly reduced COPD flare-ups in two Phase 3 trials. Promising new hope for millions of patients with chronic lung disease.
Abivax Rejects Rumors of Exclusive AstraZeneca Due Diligence Until March 23
French biotech company Abivax strongly rejects media claims that it gave AstraZeneca secret access to its data for a possible buyout until March 23, calling the reports "unfounded rumors."
AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
Upstream Bio's Asthma Drug Hits Goal but Misses Top Hopes
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
AstraZeneca Rumored to Bid €176 Per Share for French Biotech Abivax Amid M&A Buzz
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.